Description
Anti-FGF19 Antibody, Non-Fucosylated (BioBet-881ZP) is a mouse monoclonal IgG antibody against FGF19. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FGF19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FGF19
Full Name
fibroblast growth factor 19
Background
The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. This growth factor is a high affinity, heparin dependent ligand for FGFR4. Expression of this gene was detected only in fetal but not adult brain tissue. Synergistic interaction of the chick homolog and Wnt-8c has been shown to be required for initiation of inner ear development.
Alternative Names
FGF19; fibroblast growth factor 19; FGF-19
Gene ID
9965
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with FGF19 include Functional Diarrhea and Sarcomatoid Transitional Cell Carcinoma.
Related Pathways
Its related pathways are RET signaling and Signaling by GPCR.
Function
After the cascade of JNK and ERK1/2 is positive, it participates in the inhibition of bile acid biosynthesis by down-regulating the expression of CYP7A1. Stimulates the uptake of glucose by fat cells. Activity requires the presence of KLB and FGFR4.
Post-translational modifications
1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-881ZP
Description
The anti-FGF19 antibody provide important therapeutic and diagnostic agents for use in targeting pathological conditions associated with expression and/or activity of the FGF19-FGFR4 pathways.
Antibody Indication
Cancer
